Clinical Trials Logo

Metastatic Bladder Cancer clinical trials

View clinical trials related to Metastatic Bladder Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04887831 Terminated - Bladder Cancer Clinical Trials

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

PRESERVE3
Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in patients receiving first-line treatment for advanced/metastatic bladder cancer.

NCT ID: NCT03498196 Terminated - Bladder Cancer Clinical Trials

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

Start date: December 14, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot study of avelumab in patients with non-metastatic, muscle invasive bladder cancer who are eligible for radical cystectomy (RC), but are ineligible for cisplatin based neoadjuvant therapy. The target recruitment is 10 evaluable patients for this window of opportunity study. Pre- and post-treatment tumor samples from transurethral resection of the bladder tumor and RC will be used for study endpoints.